The entire case for Sellas Life Sciences now rests on one number: a hazard ratio of 0.636 or better. That is the statistical threshold its phase 3 REGAL trial must clear to prove that Galinpepimut-S (GPS) extends survival in acute myeloid leukemia. With 78 of the required 80 deaths already recorded, the database lock and unblinding are imminent – a verdict that will determine whether the stock’s breathtaking advance has fundamental legs or was simply a speculative mirage.
The rally itself has been extraordinary. From a 52-week low of €1.22 in November 2025, shares surged 947% to €13.00 at Thursday’s close, having touched an all-time high of €15.25 just three days earlier. The market capitalization now stands at €2.54 billion – a figure that could evaporate if the trial misses its primary endpoint. Over the past 30 days alone, the stock has gained 83.62%, with a weekly advance of 20.93%.
Yet analysts are far from convinced. The consensus price target sits at €8.74, implying a 32.8% downside from current levels. That gap between market price and analyst models rarely appears without reason. In oncology, retail investors often bid up shares on hope, while professionals must account for the brutal failure rates of drug development. The result is what the industry calls a “hope premium” – one that can vanish the moment a study disappoints.
Technical indicators reinforce the caution. The 14-day relative strength index has climbed to 72.1, with some readings even touching 73.7, firmly in overbought territory. The stock trades 82% to 90% above its 50-day moving average – a stretch that historically precedes a consolidation or correction. Annualized 30-day volatility of 123.59% underscores that extreme swings in either direction are the norm, not the exception.
The bear case is straightforward. If REGAL fails to achieve a hazard ratio of 0.636, Sellas has no other commercial-stage product to cushion the blow. The distance from the current price to the 52-week low of €1.22 – some 964% – illustrates how much speculative value is at risk. In a failure scenario, the 200-day moving average near €3.67 could become a relevant floor.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Bulls, however, point to several promising signals. The longer the trial takes to reach its 80th event, the longer patients on GPS appear to survive – though that can only be proven after unblinding. More tangibly, recent changes to executive contracts have added change-of-control clauses, a move that has ignited takeover speculation. If positive data emerge, a large pharmaceutical company could swoop in, with management financially protected by the new provisions.
Sellas also has a second card to play: SLS009, a CDK9 inhibitor in phase 2 testing for first-line AML. Data are expected in the fourth quarter of 2026. A positive REGAL outcome would further validate the company’s WT1 platform, potentially opening applications beyond leukemia. Financially, the company is on solid ground, with €107.1 million in cash at the end of the first quarter – enough to navigate the post-data period without liquidity pressure.
The divergence within the oncology sector adds context. While Sellas has rocketed higher, other biotechs have stumbled. Ascelia Pharma, for instance, dropped 70% after an FDA rejection. Revolution Medicines has posted solid clinical data without the same speculative price action. Capital appears to have concentrated on Sellas as a binary bet – all or nothing.
The decision window is the third quarter of 2026. The market will be watching two signals especially closely: the official confirmation of the 80th event and the start of unblinding, and any concrete details on takeover or partnership discussions. If the hazard ratio meets the 0.636 threshold, the 52-week high of €15.25 could quickly come back into play. If it does not, the consensus target of €8.74 – or lower – may be the more realistic destination. For a stock that has risen nearly tenfold in seven months, the next few weeks will decide whether that climb was a prelude to a new plateau or a peak before a steep descent.
Ad
Sellas Life Sciences Stock: Buy or Sell?! New Sellas Life Sciences Analysis from July 3 delivers the answer:
The latest Sellas Life Sciences figures speak for themselves: Urgent action needed for Sellas Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 3.
Sellas Life Sciences: Buy or sell? Read more here...
